Clinical Trial Update: A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004) [Phase 2]

View source ↗

Summary

The Phase 2 MK-3543-004 trial evaluating Bomedemstat in polycythemia vera has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Conditions: Polycythemia Vera | Phase 2 | Status: COMPLETED